Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Misoprostol administered sublingually for second trimester pregnancy termination
ISRCTN ISRCTN72965671
ClinicalTrials.gov identifier
Public title Misoprostol administered sublingually for second trimester pregnancy termination
Scientific title
Acronym N/A
Serial number at source WHO/HRP ID A15065
Study hypothesis To compare two treatment regimens (0.4 mg misoprostol administered sublingually versus vaginally every three hours up to five doses) for the termination of pregnancy in women with a length of amenorrhoea between 14 to 20 weeks.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Armenia, Georgia, Hungary, India, Slovenia, South Africa, Viet Nam, Zambia
Disease/condition/study domain Induced abortion
Participants - inclusion criteria 1. Healthy women
2. Eligible for and requesting legal termination of second trimester pregnancy
Participants - exclusion criteria No exclusion criteria
Anticipated start date 01/12/2001
Anticipated end date 01/12/2002
Status of trial Completed
Patient information material
Target number of participants 680
Interventions Misoprostol (0.4 mg) either vaginally or sublingually every three hours up to five doses.

Approximate duration of involvement in the study for each subject: first follow up at 15 days post-treatment, another follow-up visit will be carried out according to the practice of the hospital.
Primary outcome measure(s) 1. The effectiveness to induce complete or partial abortion/induction-to-abortion interval
2. The frequency of side effects
3. Acceptability of treatment to women
Secondary outcome measure(s) No secondary outcome measures
Sources of funding United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
Trial website
Publications 2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15327617
2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18794161
Contact name Dr  Helena  von Hertzen
  Address World Health Organization
20 Avenue Appia
  City/town Geneva-27
  Zip/Postcode CH-1211
  Country Switzerland
  Email vonhertzenh@who.int
Sponsor UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction
  Address World Health Organization
20 Avenue Appia
  City/town Geneva-27
  Zip/Postcode CH-1211
  Country Switzerland
  Sponsor website: http://www.who.int/reproductive-health/hrp/
Date applied 19/03/2004
Last edited 11/12/2008
Date ISRCTN assigned 01/04/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central